妊娠期糖尿病筛查:美国预防服务工作组更新证据报告与系统评价
2项非随机干预研究;直接比较筛查与不筛查获益的证据有限(4项观察性研究,结果不一致)。一步法(IADPSG)与两步法(Carpenter和Coustan)筛查相比,GDM检出率更高(11.5% vs 4.9%),但未改善健康结局。基于8项RCT和1项非随机研究(n=3982),治疗GDM显著降低初次剖宫产、肩难产、巨大儿、大于胎龄儿、产伤及新生儿ICU入院风险,早产风险降低不显著。
要点
- 治疗妊娠期糖尿病可降低初次剖宫产(RR 0.70, 95%CI 0.54-0.91)、巨大儿(RR 0.53, 95%CI 0.41-0.68)、大于胎龄儿(RR 0.56, 95%CI 0.47-0.66)风险。
- 治疗还降低肩难产(RR 0.42, 95%CI 0.23-0.77)、产伤(OR 0.33, 95%CI 0.11-0.99)及新生儿ICU入院(RR 0.73, 95%CI 0.53-0.99)风险;早产风险降低不显著(RR 0.75, 95%CI 0.56-1.01)。
- 一步法(IADPSG)与两步法(Carpenter和Coustan)筛查相比,GDM检出率更高(11.5% vs 4.9%),但未显著改善健康结局。
- 直接比较筛查与不筛查获益的证据有限(仅4项观察性研究,结果不一致且有方法学局限);筛查未显著增加严重或长期危害。
- 妊娠24周及以后,口服葡萄糖激发试验140 mg/dL界值对Carpenter和Coustan标准的敏感性82%、特异性82%;135 mg/dL界值敏感性93%、特异性79%。
适用人群与场景
- 妊娠期女性,筛查时机为妊娠24周及以后(原文提及口服葡萄糖激发试验和空腹血糖试验在此时期评估)。
- 研究纳入英文干预研究(筛查和治疗)、观察性筛查研究及筛查试验准确性的前瞻性研究。
诊断标准与关键阈值
- 口服葡萄糖激发试验140 mg/dL界值对Carpenter和Coustan标准:敏感性82%、特异性82%;135 mg/dL界值:敏感性93%、特异性79%。
- 口服葡萄糖激发试验140 mg/dL界值对National Diabetes Group Data标准:敏感性85%、特异性81%。
- 空腹血糖85 mg/dL界值对Carpenter和Coustan标准:敏感性88%、特异性73%;90 mg/dL界值:敏感性81%、特异性82%。
- 一步法筛查采用国际糖尿病与妊娠研究组(IADPSG)标准;两步法采用Carpenter和Coustan标准。
处置流程与药物剂量
- 原文未提及具体的治疗药物、剂量、给药途径、频次或目标值。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 直接比较筛查与不筛查获益的证据仅来自4项观察性研究,结果不一致且有方法学局限;筛查未显著增加严重或长期危害。
- 治疗GDM(8项RCT和1项非随机研究,n=3982):初次剖宫产RR 0.70(95%CI 0.54-0.91;ARD 5.3%)、肩难产RR 0.42(95%CI 0.23-0.77;ARD 1.3%)、巨大儿RR 0.53(95%CI 0.41-0.68;ARD 8.9%)、大于胎龄儿RR 0.56(95%CI 0.47-0.66;ARD 8.4%)、产伤OR 0.33(95%CI 0.11-0.99;ARD 0.2%)、新生儿I
证据类型、等级与局限
- 证据类型:系统评价与meta分析,为美国预防服务工作组(USPSTF)更新证据报告。
- 证据等级或推荐强度:原文未提及。
- 局限性:直接比较筛查与不筛查获益的证据有限(仅4项观察性研究,结果不一致且有方法学局限);一步法与两步法比较的RCT未显示健康结局改善;治疗获益证据来自RCT和非随机研究。
对床旁实践的改变
- 对于妊娠24周及以后的妊娠期糖尿病,治疗可降低初次剖宫产、肩难产、巨大儿、大于胎龄儿、产伤及新生儿ICU入院风险,支持对此人群进行治疗。
- 一步法(IADPSG)筛查较两步法(Carpenter和Coustan)检出更多GDM(11.5% vs 4.9%),但未显著改善健康结局,选择筛查策略时需权衡检出率与后续干预。
- 直接比较筛查与不筛查获益的证据有限,临床决策应结合其他证据;筛查未显著增加严重或长期危害。
- 口服葡萄糖激发试验或空腹血糖试验可作为筛查试验,不同界值的敏感性和特异性如上,需注意界值选择对检出率的影响。
指南或共识出处
- 原文未提及具体的指南或共识名称(本文为美国预防服务工作组更新证据报告与系统评价,非指南本身)。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Gestational diabetes is associated with several poor health outcomes.
OBJECTIVE: To update the 2012 review on screening for gestational diabetes to inform the US Preventive Services Task Force.
DATA SOURCES: MEDLINE, EMBASE, and CINAHL (2010 to May 2020), ClinicalTrials.gov, reference lists; surveillance through June 2021.
STUDY SELECTION: English-language intervention studies for screening and treatment; observational studies on screening; prospective studies on screening test accuracy.
DATA EXTRACTION AND SYNTHESIS: Dual review of titles/abstracts, full-text articles, and study quality. Single-reviewer data abstraction with verification. Random-effects meta-analysis or bivariate analysis (accuracy).
MAIN OUTCOMES AND MEASURES: Pregnancy, fetal/neonatal, and long-term health outcomes; harms of screening; accuracy.
RESULTS: A total of 76 studies were included (18 randomized clinical trials [RCTs] [n = 31 241], 2 nonrandomized intervention studies [n = 190], 56 observational studies [n = 261 678]). Direct evidence on benefits of screening vs no screening was limited to 4 observational studies with inconsistent findings and methodological limitations. Screening was not significantly associated with serious or long-term harm. In 5 RCTs (n = 25 772), 1-step (International Association of Diabetes and Pregnancy Study Group) vs 2-step (Carpenter and Coustan) screening was significantly associated with increased likelihood of gestational diabetes (11.5% vs 4.9%) but no improved health outcomes. At or after 24 weeks of gestation, oral glucose challenge tests with 140- and 135-mg/dL cutoffs had sensitivities of 82% and 93%, respectively, and specificities of 82% and 79%, respectively, against Carpenter and Coustan criteria, and a test with a 140-mg/dL cutoff had sensitivity of 85% and specificity of 81% against the National Diabetes Group Data criteria. Fasting plasma glucose tests with cutoffs of 85 and 90 mg/dL had sensitivities of 88% and 81% and specificities of 73% and 82%, respectively, against Carpenter and Coustan criteria. Based on 8 RCTs and 1 nonrandomized study (n = 3982), treatment was significantly associated with decreased risk of primary cesarean deliveries (relative risk [RR], 0.70 [95% CI, 0.54-0.91]; absolute risk difference [ARD], 5.3%), shoulder dystocia (RR, 0.42 [95% CI, 0.23-0.77]; ARD, 1.3%), macrosomia (RR, 0.53 [95% CI, 0.41-0.68]; ARD, 8.9%), large for gestational age (RR, 0.56 [95% CI, 0.47-0.66]; ARD, 8.4%), birth injuries (odds ratio, 0.33 [95% CI, 0.11-0.99]; ARD, 0.2%), and neonatal intensive care unit admissions (RR, 0.73 [95% CI, 0.53-0.99]; ARD, 2.0%). The association with reduction in preterm deliveries was not significant (RR, 0.75 [95% CI, 0.56-1.01]).
CONCLUSIONS AND RELEVANCE: Direct evidence on screening vs no screening remains limited. One- vs 2-step screening was not significantly associated with improved health outcomes. At or after 24 weeks of gestation, treatment of gestational diabetes was significantly associated with improved health outcomes.
参考来源
- Pillay J, Donovan L, Guitard S, et al. Screening for Gestational Diabetes: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021. PMID: 34374717. doi:10.1001/jama.2021.10404
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。